Rehman Rana Zia Ur, Parisi Federico, Ashraf Noman, Chatterjee Meenakshi, Frantz Robert P, Hemnes Anna R, Manyakov Nikolay V, Carrasco-Zevallos Oscar M, Yardibi Tarik, Selej Mona, Mansi Tommaso, Dunnmon Preston, Kaliukhovich Dzmitry A
Janssen Pharmaceutical Companies of Johnson & Johnson High Wycombe Buckinghamshire UK.
Janssen Pharmaceutical Companies of Johnson & Johnson Cambridge Massachusetts USA.
Pulm Circ. 2025 May 26;15(2):e70097. doi: 10.1002/pul2.70097. eCollection 2025 Apr.
There is a need for objective, continuous and remote assessment of exercise capacity in patients with pulmonary arterial hypertension (PAH). Using data from the TRACE study, in which 108 adult patients with PAH were continuously monitored with a wrist-worn accelerometer, we evaluated whether actigraphy can facilitate continuous monitoring of exercise capacity. Distributions of step rate, distance and duration of patient's walking bouts were estimated at baseline, Week 16 and Week 24 using 2-week periods of actigraphy data. Twenty-one metrics per walking bout characteristic were described (mean, standard deviation, 19 percentiles [5th-95th]). The relationships between these metrics and the 6-min walk distance (6MWD), Borg dyspnea index (BDI), and the PAH Symptoms and Impact questionnaire (PAH-SYMPACT) Physical Impact domain score were assessed at the three timepoints. Test-retest reliability, and discriminant and known-group validity of each metric were also evaluated. All metrics of step rate and bout distance were significantly correlated with 6MWD (Pearson's correlation coefficients: 0.34-0.67; < 0.005) and the PAH-SYMPACT Physical Impact domain score (Pearson's correlation coefficients: -0.51 to -0.32; < 0.05) at all timepoints. Negative correlations were also observed with the BDI and the actigraphy-derived metrics, with the majority reaching significance. Strong test-retest reliability was demonstrated (intra-class correlation coefficient ≥ 0.70). The metrics differentiated well between patients with varying disease severity levels. In conclusion, actigraphy-derived metrics of patients' walking bouts correlate significantly with 6MWD, BDI and physical impacts of PAH, indicating the utility of actigraphy in facilitating continuous monitoring of exercise capacity in adult patients with PAH.
ClinicalTrials.gov: NCT03078907; URL: clinicaltrials.gov.
肺动脉高压(PAH)患者需要对运动能力进行客观、持续和远程评估。利用TRACE研究的数据,我们使用腕部佩戴的加速度计对108名成年PAH患者进行了持续监测,以评估活动记录仪是否有助于对运动能力进行持续监测。在基线、第16周和第24周,使用为期2周的活动记录仪数据估计患者步行时段的步频、距离和持续时间分布。描述了每个步行时段特征的21个指标(均值、标准差、19个百分位数[第5-95百分位数])。在三个时间点评估了这些指标与6分钟步行距离(6MWD)、Borg呼吸困难指数(BDI)以及PAH症状与影响问卷(PAH-SYMPACT)身体影响领域得分之间的关系。还评估了每个指标的重测信度、判别效度和已知组效度。所有步频和时段距离指标在所有时间点均与6MWD(Pearson相关系数:0.34 - 0.67;P < 0.005)和PAH-SYMPACT身体影响领域得分(Pearson相关系数:-0.51至-0.32;P < 0.05)显著相关。BDI与活动记录仪得出的指标之间也观察到负相关,大多数具有显著性。显示出很强的重测信度(组内相关系数≥0.70)。这些指标在不同疾病严重程度水平的患者之间有很好的区分度。总之,活动记录仪得出的患者步行时段指标与6MWD、BDI以及PAH的身体影响显著相关,表明活动记录仪在促进对成年PAH患者运动能力的持续监测方面具有实用性。
ClinicalTrials.gov:NCT03078907;网址:clinicaltrials.gov。